Notice: Constant automattic\jetpack\extensions\social_previews\FEATURE_NAME already defined in /home2/theprkho/public_html/thepharmatimes.in/wp-content/plugins/jetpack/extensions/blocks/social-previews/social-previews.php on line 14
Yarra®1.8µm UHPLC Size Exclusion Column Delivers Increased Separation of High Molecular Weight Biomolecules - The Pharma Times | Pharma & Health Care News Portal
Categories: Latest

Yarra®1.8µm UHPLC Size Exclusion Column Delivers Increased Separation of High Molecular Weight Biomolecules

Torrance, August 23, 2016: Phenomenex Inc., a global leader in the research and manufacture of advanced technologies for the separation sciences, introduces Yarra 1.8µm SEC-X300– a high-resolution gel filtration (GFC)/aqueous size-exclusion (SEC) column for the separation of high molecular weight (HMW) biomolecules on HPLC and UHPLC systems. With a wide separation range of 10K to 700KDa and high efficiency, SEC-X300 is ideal for separating and characterizing monoclonal antibody (mAb) aggregates,antibody drug conjugates (ADCs)and biosimilars in drug discovery and development research. The HMW focus of the SEC-X300 complements the low molecular weight range (1K-450KDa) of the existing Yarra 1.8µm SEC-X150 column, providing two versatile separation tools for biopharmaceutical research.The proprietary Yarra surface chemistry, combined with bio-inert column hardware, reduces sample adsorption compared to other GFC/SEC columns currently on the market, providing improved recovery and more accurate quantitation of biomolecules at a lower price point. The SEC-X150 and -X300 media are both now available in 150 and 300 mm column lengths, for analytical flexibility to increase speed or further increase resolution.

Because Yarra SEC-X150 and -X300 columns typically operate at back pressures below 3,500 psi on traditional HPLC and UHPLC systems, they can deliver improved performance (greater resolution, better peak shape and faster analysis time) compared to existing 3µm and 5µm GFC/SEC column methods. Designed and manufactured for stability, reproducibility and long product life, all Yarra phases are supported by a superior product quality and performance guarantee.

“Yarra 1.8µm SEC-X300 and -X150 were expertly developed and fine-tuned to offer our customers a wider applicability for popular biomolecule separations such as mAb fragmentation and ADC characterization,” explained Simon Lomas, strategic marketing manager for Phenomenex. “Our new Yarra SEC-X150 and -X300 columns additionally feature greater media and hardware inertness to overcome sample adsorption.”

Phenomenex is a global technology leader committed to developing novel analytical chemistry solutions that solve the separation and purification challenges of researchers in industrial, clinical research, government and academic laboratories. From drug discovery and pharmaceutical development to food safety and environmental analysis, Phenomenex chromatography solutions accelerate science and help researchers improve global health and well-being. For more information on Phenomenex, visit www.phenomenex.com or follow the company on Twitter @Phenomenex.

Corporate Comm India(CCI Newswire)

The Pharma Times News Bureau

Recent Posts

Gleneagles Hospital Mumbai Introduces Pediatric Bone Marrow Transplant (BMT) Facility

New Delhi, May 17, 2024: In response to the growing need for specialized pediatric care,…

1 day ago

Ramaiah Memorial Hospital Launches Novel Intra-Operative Radiation Therapy (IORT);

Achieves significant advancement in Cancer Treatment to Enhance Quality of Life  As per the National…

2 days ago

Two Complex Robotic Kidney Transplant Surgeries Successfully Performed at Fortis Hospital Bannerghatta Road

-An 11-year-old boy from Yemen and a 34-year-old man from Bengaluru, both suffered from end-stage…

3 days ago

On International Nurses Day, American Oncology Institute (AOI) launches #TheExtraordinaryCareGiver Campaign as Tribute to Oncology Nurses

Mumbai, 14th May 2024 – As part of its dedication to exceptional patient care, American Oncology…

4 days ago

SOCC Unveils A New Era In Paediatric Care: Second Opinion Online Consultations For Children

Mumbai, May 11, 2024: In a landmark move for Indian healthcare, the introduction of Second…

1 week ago

India’s First Lady Surgeon Trained in Robotic Breast Surgery Performs Karnataka’s 1st Robotic Nipple Sparing Mastectomy

Bengaluru, May 08, 2024: Cancer remains the illness most feared across the globe. But to combat…

1 week ago

Notice: ob_end_flush(): failed to send buffer of zlib output compression (0) in /home2/theprkho/public_html/thepharmatimes.in/wp-includes/functions.php on line 5420